Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5604_Библиотеки_им_академика_М_И_Перельмана.pdf
Carbon-based Nanocarriers for Sustained Drug Release in Dentistry 315
ways of limiting drug requirement for a desired effect. CBNs have various subcategories, which act as opportunistic carrier in biomedical applications of delivery of
drug. They are a novelty in targeted localised delivery of drug in the oral cavity due
to its superior properties of higher capacity of drug loading, better release kinetics,
enhanced solubility and higher biocompatibility with lowered cytotoxicity.Neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease and various
life-threatening diseases like carcinomas are the newer fields of application of CBNs
as biomedical drug carriers of future.
References
1. Rajeshwari HR, Dhamecha D, Jagwani S, Rao M, Jadhav K, Shaikh S, Puzhankara L, Jalalpure
S (2019) Local drug delivery systems in the management of periodontitis. J Control Release
307:393
2. Jamaledin R, Yiu CKY, Zare EN, Niu L, Vecchione R, Chen G, Gu Z, Tay FR, Makvandi P
(2020) Advances in antimicrobial microneedle patches for combating infections. Adv Mater
32:2002129
3. Jamaledin R, Makvandi P, Yiu CKY, Agarwal T, Vecchione R, Sun W, Maiti TK, Tay FR,
Netti PA (2020) Adv Ther 3:2000171
4. Nguyen S, Hiorth M (2015) Advanced drug delivery systems for local treatment of the oral
cavity. Ther Deliv 7:117
5. Su H, Wang Y, Liu S, Wang Y, Liu Q, Liu G, Chen Q (2019) Emerging transporter-targeted
nanoparticulate drug delivery systems. Acta Pharm Sin B 9:49
6. Patel VF, Liu F, Brown MB (2011) Advances in oral transmucosal drug delivery. J Control
Release 153(2):106–116
7. Kaur N, Kokate A, Li X, Jasti B (2014) Transmucosal drug delivery. In: Mitra AK, Kwatra
D, Vadlapudi AD (eds) Drug delivery. Jones & Bartlett Learning, Burlington, MA, USA, pp
264–279
8. Chaudhary SA, Shahiwala AF (2010) Medicated chewing gum-a potential drug delivery
system. Exp Opin Drug Deliv 7(7):871–885
9. Hoffmann EM, Breitenbach A, Breitkreutz J (2011) Advances in orodispersible films for drug
delivery. Exp Opin Drug Deliv 8(3):299–316
10. Song X, Yaskell T, Klepac-Ceraj V, Lynch MC, Soukos NS (2014) Antimicrobial action of
minocycline microspheres versus 810-nm diode laser on human dental plaque microcosm
biofilms. J Periodontol 85(2):335–342
11. Elizabeth PS, Néstor MM, DavidQG (2019) Drug delivery(nano) platforms for oral and dental
applications: tissue regeneration, infection control, and cancer management. Nanobiomater
Clin Dent (2nd ed) 567 (2019)
12. Grimaudo MA, Concheiro A, Alvarez-Lorenzo C (2019) Nanogels for regenerative medicine.
J Control Release 313:148
13. Zhao Q, Lin Y, Han N, Li X, Geng HJ, Wang X, Cui Y, Wang S (2017) Mesoporous carbon
nanomaterials in drug delivery and biomedical application. Drug Deliv 24(2):94–107
14. Goldberg M, Langer R, Jia X (2007) Nanostructured materials for applications in drug delivery
and tissue engineering. J Biomater Sci Polym Ed 18(3):241–268
15. Liu J, Cui L, Losic D (2013) Graphene and graphene oxide as new nanocarriers for drug
delivery applications. Acta Biomater 9(12):9243–9257
16. Vasquez Marcano R, Tominaga TT, Khalil NM, Pedroso LS, Mainardes RM (2018) Chitosan
functionalized poly (epsilon-caprolactone) nanoparticles for amphotericin B delivery. Carbohydr Polym 202:345–354
316 A. Biswal
17. Hsiao MH, Mu Q, Stephen ZR, Fang C, Zhang M (2015) Hexanoyl-chitosan-PEG copolymer
coated iron oxide nanoparticles for hydrophobic drug delivery. ACS Macro Lett 4:403–407
18. Bhavsar C, Momin M, Gharat S, Omri A (2017) Functionalized and graft copolymers of
chitosan and its pharmaceutical applications. Exp Opin Drug Deliv 14:1189–1204
19. Wang Z, Luo T, Cao A, Sun J, Jia L, Sheng R (2018) Morphology-variable aggregates prepared
from cholesterol-containing amphiphilic glycopolymers: their protein recognition/adsorption
and drug delivery applications. Nanomaterials 8:136
20. Ferji K, Venturini P, Cleymand F, Chassenieux C, Six JL (2018) In situ glyco-nanostructure
formulation via photo-polymerization induced self-assembly. Polym Chem 9:2868–2872
21. Li J, Cai C, Li J, Li J, Li J, Sun T, Wang L, Wu H, Yu G (2018) Chitosan-based nanomaterials
for drug delivery. Molecules 23:2661
22. Sohail MF, Hussain SZ, Saeed H, Javed I, Sarwar HS, Sarwar A, Huma ZE, Rehman M,
Jahan S, Hussain I, Shahnaz G (2018) Polymeric nanocapsules embedded with ultra-small
nanoclusters for synergistic pharmacology and improved oral delivery of Docetaxel. Sci Rep
8:13304–13314
23. Ghaffarian R, Herrero EP, Oh H, Raghavan SR, Muro S (2016) Chitosan-alginate microcapsules provide gastric protection and intestinal release of ICAM-1-targeting nanocarriers,
enabling GI targeting in vivo. Adv Funct Mater 26:3382–3393
24. Park JH, Saravanakumar G, Kim K, Kwon IC (2010) Targeted delivery of low molecular
drugs using chitosan and its derivatives. Adv Drug Deliv Rev 62:28–41
25. Hoop M, Mushtaq F, Hurter C, Chen XZ, Nelson BJ, Pane S (2016) A smart multifunctional
drug delivery nanoplatform for targeting cancer cells. Nanoscale 12723–12728
26. Doane TL, Burda C (2012) The unique role of nanoparticles in nanomedicine: imaging, drug
delivery and therapy. Chem Soc Rev 41(7):2885–2911
27. Wei A, Mehtala JG, Patri AK (2012) Challenges and opportunities in the advancement of
nanomedicines. J Control Release 164(2):236–246
28. Master A, Livingston M, Gupta AS (2013) Photodynamic nanomedicine in the treatment of
solid tumors: perspectives and challenges. J Control Release 168(1):88–102
29. Taratula O, Kuzmov A, Shah M et al (2013) Nanostructured lipid carriers as multifunctional
nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control
Release 171(3):349–357
30. Sankar V, Hearnden V, Hull K, Juras DV, Greenberg MS, Kerr AR, Lockhart PB, Patton LL,
Porter S, Thornhill M (2011) Local drug delivery for oral mucosal diseases: challenges and
opportunities. Oral Dis 73–84
31. Nanci A (2003) Ten Cate’s oral histology-development, structure and function. Mosby, MO,
USA
32. Salamat-Miller N, Chittchang M, Johnston TP (2005) The use of mucoadhesive polymers in
buccal drug delivery. Adv Drug Deliv Rev 57(11):1666–1691
33. Shimono M, Clementi F (1976) Intercellular junctions of oral epithelium. I. Studies with
freeze-fracture and tracing methods of normal rat keratinized oral epithelium. J Ultrastruct
Res 56(1):121–213
34. Shojaei AH (1988) Buccal mucosa as a route for systemic drug delivery: a review. J Pharm
Pharm Sci 1(1):15–30
35. Kulkarni U, Mahalingam R, Pather SI, Li X, Jasti B (2009) Porcine buccal mucosa as an in vitro
model: relative contribution of epithelium and connective tissue as permeability barriers. J
Pharm Sci 98(2):471–483
36. Ganem-Quintanar A, Falson-Rieg F, Buri P (1997) Contribution of lipid components to the
permeability barrier of oral mucosa. Eur J Pharm Biopharm 44(2):107–120
37. Squier CA, Hall BK (1985) The permeability of skin and oral mucosa to water and horseradish
peroxidase as related to the thickness of the permeability barrier. J Invest Dermatol 84(3):176–
179
38. Sudhakar Y, Kuotsu K, Bandyopadhyay AK (2006) Buccal bioadhesive drug delivery – a
promising option for orally less efficient drugs. J Control Release 114(1):15–40
Carbon-based Nanocarriers for Sustained Drug Release in Dentistry 317
39. Li N, Sood S, WangS, Fang M, Wang P,Sun Z, YangCS, Chen X (2005) Over expression of 5lipoxygenase and cyclooxygenase 2 in Hamster and human oral cancer and chemopreventive
effects of zileuton and celecoxib. Clin Cancer Res 11(5):2089–2096
40. Hoogstraate AJ, Cullander C, Nagelkerke JF, Senel S, Verhoef JC, Junginger HE, Bodde HE
(1994) Diffusion rates and transport pathways of fluorescein isothiocyanate (FITC)-labelled
model compounds through buccal epithelium. Pharm Res 11:83–89
41. Madhav NVS, Shakya AK, Shakya P, Singh K (2009) Orotransmucosal drug delivery systems:
a review. J Control Release 140(1):2–11
42. Sood S, Shiff SJ, Yang CS, Chen X (2005) Selection of topically applied non-steroidal antiinflammatory drugs for oral cancer chemoprevention. Oral Oncol 41(6):562–567
43. Harsanyi BB, Hilchie JC, Mezei M (1986) Liposomes as drug carriers for oral ulcers. J Dent
Res 65(9):1133–1141
44. Bánóczy J, Squier CA, Kremer M, Wertz PW, Kovesi G, Szende B, Dombi C (2003) The
permeability of oral leukoplakia. Eur J Oral Sci 111(4):312–315
45. Pitts NB (2004) Are we ready to move from operative to non-operative/preventive treatment
of dental caries in clinical practice? Caries Res 38(3):294–304
46. Featherstone JD (2000) The science and practice of caries prevention. J Am Dent Assoc
131(7):887–899
47. US Department of Health and Human Services (2000) Oral health in America: A report of the
surgeon general. National Institute of Dental and Craniofacial Research, National Institutes
of Health, Rockville, 308
48. Fejerskov O, Kidd EAM (eds) (2003) Dental caries: the disease and its clinical management.
Blackwell Monksgaard, Copenhagen, Denmark
49. Kidd EA, Giedrys-Leeper E, Simons D (2000) Take two dentists: a tale of root caries. Dent
Update 27(5):222–230
50. Mathur VP, Dhillon JK (2018) Dental caries: a disease which needs a ttention. Indian J Pediatr
85(3):202–206
51. Shah N, Pandey RM, Duggal R, Mathur VP, Parkash H, Sundaram KR (2007) Oral Health in
India. A report of multi-centric study. Director General of Health Services, Ministry of Health
and Family Welfare, Government of India and WHO collaborative programme
52. Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJ, Marcenes W (2006) Global
burden of Merin RL: results of periodontal treatment. In: Carranza’s clinical periodontology.
St Louis, WB Saunders, pp 1206–1214
53. Novak MJ (2006) Classification of diseases and conditions affecting the periodontium. In:
Carranza’s clinical periodontology. St Louis, WB Saunders, pp 100–109
54. Quirynen M, Teughels W, Kinder Haake S, Newman MG (2006) Microbiology of periodontal
diseases. In: Carranza’s clinical periodontology. St Louis, WB Saunders, pp 134–169
55. Hinrichs JE (2006) The role of dental calculus and other predisposing factors. In: C arranza’s
clinical periodontology. St Louis, WB Saunders, pp 170–192
56. Schroeder HE, DeBoever J (1970) The structure of microbial dental plaque. In: Dental plaque.
Edinburgh, Livingstone, p 49
57. Zambon JJ (1996) Periodontal diseases: microbial factors. Ann Periodontol 1(1):879–892
58. Kinane DF (2001) Causation and pathogenesis of periodontal disease. Periodontol 25(1):8–20
59. Haffajee A, Dzink J, Socransky S (1988) Effect of modified Widman flap surgery and
systemic tetracycline on the subgingival microbiota of periodontal lesions. J Clin Periodontol
15(4):255–262
60. van WinkelhoffAJ, van der VeldenU, de Graaff J (1988) Microbial succession in recolonizing
deep periodontal pockets after single course of supra- and subgingival debridement. J Clin
Periodontol 15(2):116–122
61. Mahanonda R, Seymour G, Powell L, Good M, Halliday J (1991) Effect of initial treatment of
chronic inflammatory periodontal disease on the frequency of peripheral blood Tlymphocytes
specific to periodontopathic bacteria. Oral Microbiol Immunol 6(4):221–227
62. Haffajee A, Socransky S, Dzink J, TaubmanM, Ebersole J (1988) Clinical, microbiological and
immunological features of subjects with refractory periodontal diseases. J Clin Periodontol
15(6):390–398
318 A. Biswal
63. Dzink J, Socransky S, Haffajee A (1988) The predominant cultivable microbiota of active and
inactive lesions of destructive periodontal diseases. J Clin Periodontol 15(5):316–323
64. Lai CH, Listgarten M, Shirakawa M, Slots J (1987) Bacteroides forsythus in adult gingivitis
and periodontitis. Oral Microbiol Immunol 2(4):152–157
65. Zambon JJ, Christersson LA, Slots J (1983) Actinobacillus actinomycetemcomitans in human
periodontal disease. Prevalence in patient groups and distribution of biotypes and serotypes
within families. J Periodontol 54:707–711
66. Genco R, Zambon J, Christersson L (1988) The origin of periodontal infections. Adv Dent
Res 2(2):245–259
67. Toumba K, Curzon M (2005) A clinical trial of a slow-releasing fluoride device in children.
Caries Res 39(3):195–200
68. Keegan GM, Smart JD, Ingram MJ, Barnes LM, Burnett GR, Rees GD (2012) Chitosan
microparticles for the controlled delivery of fluoride. J Dent 40(3):229–240
69. De Francisco LMB, Cerquetani JA, Bruschi ML (2013) Development and characterization
of gelatin and ethylcellulose microparticles designed as platforms to delivery fluoride. Drug
Dev Ind Pharm 39(11):1644–1650
70. Hernández-Sierra JF, Ruiz F,Cruz Pena DC, Martínez-Gutiérrez F,Martínez AE, Guillén AJP,
Tapia-Pérez H, Castañón GM (2008) The antimicrobial sensitivity of Streptococcus mutans
to nanoparticles of silver, zinc oxide, and gold. Nanomedicine 4(3):237–240
71. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kour JB, Ramírez JT, YacamanMJ (2005)
The bactericidal effect of silver nanoparticles. Nanotechnology 16(10):2346
72. Yee R, Holmgren C, Mulder J, Lama D, Walker D, Van Palenstein Helderman W (2009)
Efficacy of silver diamine fluoride for arresting caries treatment. J Dent Res 88(7):644–647
73. Dahlén G (2009) Bacterial infections of the oral mucosa. Periodontol 49(1):13–38
74. Samaranayake LP, Keung Leung W, Jin L (2009) Oral mucosal fungal infections. Periodontology 49(1):39–59
75. Slots J (2009) Oral viral infections of adults. Periodontol 49(1):60–86
76. Petersen P-E (2006) Policy for prevention of oral manifestations in HIV/AIDS: the approach
of the WHO Global Oral Health Program. Adv Dent Res 19(1):17–20
77. Patton L, Ramirez-Amador V, Anaya-Saavedra G, Nittayananta W,Carrozzo M, Ranganathan
K (2013) Urban legends series: oral manifestations of HIV infection. Oral Dis 19(6):533–550
78. Leao JC, Ribeiro C, Carvalho AA, Frezzini C, Porter S (2009) Oral complications of HIV
disease. Clinics 64(5):459–470
79. Mosel D, Bauer R, Lynch D, Hwang S (2011) Oral complications in the treatment of cancer
patients. Oral Dis 17(6):550–559
80. Tariq M, Iqbal Z, Ali J, Baboota S, Talegaonkar S, Ahmad Z, Sahni JK (2012) Treatment
modalities and evaluation models for periodontitis. Int J Pharm Investig 2(3):106
81. Vyas S, Sihorkar V,Mishra V (2000) Controlled and targeted drug delivery strategies towards
intraperiodontal pocket diseases. J Clin Pharm Ther 25(1):21–42
82. Qin Y, Yuan M, Li L, Li W, Xue J (2012) Formulation and evaluation of in situ forming PLA
implant containing tinidazole for the treatment of periodontitis. J Biomed Mater Res B Appl
Biomater 100(8):2197–2202
83. Kilicarslan M, Koerber M, Bodmeier R (2014) In situ forming implants for the delivery of
metronidazole to periodontal pockets. Formulation and drug release studies. Drug Dev Ind
Pharm 40(5):619–624
84. De Sousa FO, Blanco-Mendez J, Perez-Estevez A, SeoanePrado R, Luzardo-Alvarez A (2012)
Effect of zein on biodegradable inserts for the delivery of tetracycline within periodontal
pockets. J Biomater Appl 27(2):187–200
85. Reise M, Wyrwa R, Müller U, Zylinski M, Völpel A, Schnabelrauch M, Berg A, Jandt KD,
Watts DC, Sigusch BW (2012) Release of metronidazole from electrospun poly(l-lactide-co-d/
l-lactide) fibers for local periodontitis treatment. Dent Mater 28(2):179–188
86. Sundararaj SC, Thomas MV, Peyyala R, Dziubla TD, Puleo DA (2013) Design of a multiple
drug delivery system directed at periodontitis. Biomaterials 34(34):8835–8842
Carbon-based Nanocarriers for Sustained Drug Release in Dentistry 319
87. Sharma A, Pradeep AR (2011) Clinical efficacy of 1% alendronate gel as a local drug delivery
system in the treatment of chronic periodontitis. A randomized, controlled clinical trial. J
Periodontol 83(1):11–18
88. Paderni C, Compilato D, Giannola LI, Campisi G (2012) Oral local drug delivery and new
perspectivesin oral drug formulation. Oral Surg Oral Med Oral Pathol Oral Radiol 114(3):25–
34
89. Peppas N, Bures P, Leobandung W, Ichikawa H (2000) Hydrogels in pharmaceutical
formulations. Eur J Pharm Biopharm 50(1):27–46
90. Nazar H, Roldo M, Fatouros DG, Van Der Merwe SM, Tsibouklis J (2012) Hydrogels in
mucosal delivery. Ther Deliv 3(4):535–555
91. Sharpe LA, Daily AM, Horava SD, Peppas NA (2014) Therapeutic applications of hydrogels
in oral drug delivery. Exp Opin Drug Deliv 11(6):901–915
92. Mendes A, Silva A, Catita J, Cerqueira F, Gabriel C, Lopes C (2013) Miconazole-loaded
nanostructured lipid carriers (NLC) or local delivery to the oral mucosa: improving antifungal
activity. Colloids Surf B Biointerfaces 111:755–763
93. Tiyaboonchai W, Rodleang I, Ounaroon A (2014) Mucoadhesive polyethylenimine-dextran
sulfate nanoparticles containing Punica granatum peel extract as a novel sustained-release
antimicrobial. Pharm Dev Technol 20(4):426–432
94. Warnakulasuriya S (2009) Global epidemiology of oral and oropharyngeal cancer. Oral Oncol
45(4):309–316
95. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics.
CA Cancer J Clin 61(2):69–90
96. Marur S, D’souza G, WestraWH, Forastiere AA (2010) HPVassociated head and neck cancer:
a virus-related cancer epidemic. Lancet Oncol 11(8):781–789
97. Koch W, Nance M (2010) Classification, clinical features, and molecular genetic models.
In: Olshan AF (ed) Epidemiology, pathogenesis, and prevention of head and neck cancer.
Springer, NY, USA, pp 1–21
98. Calixto G, Bernegossi J, Fonseca-Santos B, Chorilli M (2014) Nanotechnology-based drug
delivery systems for treatment of oral cancer: a review. Int J Nanomedicine 9:3719
99. Endo K, Ueno T, Kondo S et al (2013) Tumor-targeted chemotherapy with the nanopolymerbased drug NC-6004 for oral squamous cell carcinoma. Cancer Sci 104(3):369–374
100. Park K, Robinson JR (1984) Bioadhesive polymers as platforms for oral-controlled drug
delivery: method to study bioadhesion. Int J Pharm 19(2):107–127
101. Vincent HL (1999) Release, L. Release, encyclopaedia of controlled drug delivery(Mathiowitz
E (ed)), vols 1 and 2. John Wiley & Sons, Inc., New York, NY, USA, p 1057
102. Taboada GM, Yang K, Pereira MJN, Liu SS, Hu Y, Karp JM, Artzi N, Lee Y (2020)
Overcoming the translational barriers of tissue adhesives. Nat Rev Mater 5(4):310–329
103. Ge L, Chen S (2020) Recent advances in tissue adhesives for clinical medicine. Polymers
12(4):939
104. Nethi SK, Das S, Patra CR, Mukherjee S (2019) Recent advances in inorganic nanomaterials
for wound-healing applications. Biomater Sci 7:2652–2674
105. Coulthard P,WorthingtonH, Esposito M, Elst M, WaesOJ (2004) Tissue adhesives for closure
of surgical incisions. Cochrane Datab Syst Rev 11:CD004287
106. Deng Y, Ediriwickrema A, Yang F, Lewis JM, Girardi M, Saltzman WM (2015) A sunblock
based on bioadhesive nanoparticles. Nat Mater 14(12):1278–1285
107. Kim B-Y,Jeong JH, Park K, Kim J-D (2005) Bioadhesiveinteraction and hypoglycemic effect
of insulin-loaded lectin–microparticle conjugates in oral insulin delivery system. J Control
Release 102(3):525–538
108. Ahmady A, Abu Samah NH (2021) A review: gelatine as a bioadhesive material for medical
and pharmaceutical applications. Int J Pharm 608:121037
109. Roy S, Pal K, Anis A, Pramanik K, Prabhakar B (2009) Polymers in mucoadhesive drugdelivery systems: a brief note. Des Monomers Polym 12:483–495
110. Chatterjee B, Amalina N, Sengupta P, Mandal UK (2017) Mucoadhesive polymers and their
mode of action: a recent update. J Appl Pharm Sci 7(5):195–203
320 A. Biswal
111. Barua S, Kim H, Jo K, Seo CW, Park TJ, Bin Lee K, Yun G, Oh K, Lee J (2016) Drug delivery
techniques for buccal route: formulation strategies and recent advances in dosage form design.
J Pharm Investig 46:593–613
112. Bepete G, Coleman KS (2019) Carbon nanotubes: electronic structure and spectroscopy in
comprehensive nanoscience and nanotechnology 205–218
113. J.P. Raval, P. Joshi, D.R. Chejara, A.M. Inamuddin, A. Mohammad, Carbon nanotube for
targeted drug delivery, In Applications of nanocomposite Materials in drug delivery, (Elsevier,
2018) pp. 203–216
114. Beg S, Rahman M, Jain A, Saini S, Hasnain MS, Swain S et al (2018) Emergence in the
functionalized carbon nanotubes as smart nanocarriers for drug delivery applications. In:
Fullerenes, graphenes and nanotubes: a pharmaceutical approach. Elsevier, pp 105–133
115. Liang F, Chen B (2009) A review on biomedical applications of single walled carbon
nanotubes. Curr Med Chem 17(1):10–24
116. Shen C, Brozena AH, Wang Y (2011) Double-walled carbon nanotubes: challenges and
opportunities. Nanoscale 3(2):503–518
117. Punbusayakul N, Talapatra S, Ajayan PM, Surareungchai W (2013) Label-free as-grown
double wall carbon nanotubes bundles for Salmonella typhimurium immunoassay. Chem
Cent J 7(1):102–108
118. Béduer A, Seichepine F, Flahaut E, Loubinoux I, Vaysse L, Vieu C (2012) Elucidation of the
role of carbon nanotube patterns on the development of cultured neuronal cells. Langmuir
28(50):17363–17371
119. Ganji DD, Kachapi SHH (2015) Semi nonlinear analysis in carbon nanotube In: Application
of nonlinear systems in nanomechanics and nanofluids. Elsevier, pp 13–70
120. Bhatt A, Jain A, Gurnany E, Jain R, Modi A, Jain A (2016) Carbon nanotubes: a promising
carrier for drug delivery and targeting, In: Nanoarchitectonics for smart delivery and drug
targeting. Elsevier, pp. 465–501
121. Matta-Domjan B, King A, Totti S, Matta C, Dover G, Martinez P, Zakhidov A, Ragione RL,
Macedo H, Jurewicz I, Dalton A, Velliou EG (2018) Biophysical interactions between pancreatic cancer cells and pristine carbon nanotube substrates: potential application for pancreatic
cancer tissue engineering. J Biomed Mater Res 106(5):1637–1644
122. Crevillen AG, Escarpa A, Garcia CD (2019) Carbon-based nanomaterials in analytical
chemistry in carbon-based nanomaterials in analytical chemistry 1–36
123. Hernandez Y, Pang S, Feng X, Müllen K (2012) Graphene and its synthesis in polymer science:
a comprehensive reference 415–438
124. Pan D, Zhang J, Li Z, Wu M (2010) Hydrothermal route for cutting graphene sheets into
blue-luminescent graphene quantum dots. Adv Mater Weinheim 22(6):734–738
125. Mousavi SM, Soroshnia S, Hashemi SA, Babapoor A, Ghasemi Y, Savardashtaki A, Amani
AM (2019) Graphene nano-ribbon based high potential and efficiency for DNA,cancer therapy
and drug delivery applications. Drug Metab Rev 51(1):91–104
126. Bondon N, Raehm L, Charnay C, Boukherroub R, Durand JO (2020) Nanodiamonds for
bioapplications, recent developments. J Mater Chem B 8(48):10878–10896
127. Reina G, Orlanducci S, Cairone C, Tamburri E, Lenti S, Cianchetta I, Rossi M, Terranova ML
(2015) Rhodamine/nanodiamond as a system model for drug carrier. J Nanosci Nanotechnol
15(2):1022–1029
128. Tinwala H, Wairkar S (2019) Production, surface modification and biomedical applications
of nanodiamonds: a sparkling tool for theranostics. Mater Sci Eng C 97:913–931
129. Gu M, Toh TB, Hooi L, Lim JJ, Zhang X, Chow EK (2019) Nanodiamond-mediated
delivery of a G9a inhibitor for hepatocellular carcinoma therapy. ACS Appl Mater Interface
11(49):45427–45441
130. Turcheniuk K, Mochalin VN (2017) Biomedical applications of nanodiamond (review).
Nanotechnology 28(25):252001
131. Zaytseva O, Neumann G (2016) Carbon nanomaterials: production, impact on plant
development, agricultural and environmental applications. Chem Biol Technol Agric 3(1):17
132. Hirsch A (2010) The era of carbon allotropes. Nat Mater 9(11):868–871
Carbon-based Nanocarriers for Sustained Drug Release in Dentistry 321
133. Moussa F (2018) Fullerene and derivativesfor biomedical applications. In: Nanobiomaterials:
nanostructured materials for biomedical applications 113–136
134. Streicher RM, Schmidt M, Fiorito S (2007) Nanosurfaces and nanostructures for artificial
orthopedic implants. Nanomedicine 2:861–874
135. Yang D, Ionescu MI (2018) Metal oxide–carbon hyhybrid materials for application in
supercapacitors. In: Nanobiomaterials: nanostructured Materials for biomedical applications.
Elesvier, pp 113–136
136. Knoblauch R, Geddes CD (2020) Carbon nanodots in photodynamic antimicrobial therapy:
a review. Materials 13(18):4004
137. Garg B, Bisht T (2016) Carbon nanodots as peroxidase nanozymes for biosensing. Molecules
21(12):1653
138. Cohen EN, Kondiah PPD, Choonara YE, du Toit LC, Pillay V (2020) Carbon dots as
nanotherapeutics for biomedical application. Curr Pharm Des 26(19):2207–2221
139. Tian XT, Yin XB (2019) Carbon dots, unconventional preparation strategies, and applications
beyond photoluminescence. Small 15(48):1901803
140. Fang Y, Gu D, Zou Y, Wu Z, Li F, Che R, Deng Y, Tu B, Zhao D (2010) A low-concentration
hydrothermal synthesis of biocompatible ordered mesoporous carbon nanospheres with
tunable and uniform size. Angew Chem Int Ed 49:7987–7991
141. Liu J, Yang T, Wang DW, Qing G, Zhao D, Qiao SZ (2013) A facile soft-template synthesis
of mesoporous polymeric and carbonaceous nanospheres. Nat Commun 4(1):2798
142. Zhu J, Liao L, Bian X, Kong J, Yang P, Liu B (2012) PH-controlled delivery of doxorubicin
to cancer cells, based on small mesoporous carbon nanospheres. Small 8(17):2715–2720
143. Z. Xue, F. Zhang, D. Qin, D. Qin, Y. Wang,J. Zhang, J. Liu, Y. Feng, One-pot synthesis of silver
nanoparticle catalysts supported on N-doped ordered mesoporous carbon and application in
the detection of nitrobenzene. C. 69, 481–9 (2014)
144. Tanaka S, Fujimoto H, Denayer JF, Miyamoto M, Oumi Y, Miyake Y (2015) Surface modification of soft-templated ordered mesoporous carbon for electrochemical supercapacitors.
Microporous Mesoporous Mater 217:141–149
145. Wang T, Jiang H, Wan L, Zhao Q, Jiang T, Wang B (2015) Potential application of functional
porous TiO2 nanoparticles in light-controlled drug release and targeted drug delivery. Acta
Biomater 13:354–356
146. Zhang Y, Zhi Z, Jiang T, Zhang J, Wang Z, Wang S (2010) Spherical mesoporous silica
nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J Control
Release 145(3):257–263
147. Zhang Y, Wang J, Bai X, Jiang T, Zhang Q, Wang S (2012) Mesoporous silica nanoparticles
for increasing the oral bioavailability and permeation of poorly water soluble drugs. Mol
Pharm 9(3):505–513
148. Zhao Q, Wang T, Wang J, Zheng L, Jiang T, Cheng G (2012) Fabrication of mesoporous
hydroxycarbonate apatite for oral delivery of poorly water-soluble drug carvedilol. J NonCryst Solids 358(2):229–235
149. Pattnaik S, Surendra Y, Rao JV, Swain K (2020) Carbon family nanomaterials for drug delivery
applications. In: Nanoengineered biomaterials for advanced drug delivery. Elsevier, pp 421–
445
Fullerene Based Materials for Drug Delivery
Mitali Sarkar and Dhiman Santra
Abstract Selective drug delivery at the potential target with mapping for health
therapy of every individual is becoming biggest challenges over traditional drug
delivery. With the advent of nanotechnology fabrication of nanomaterials of suitable shape and size, solubility, material compositions and surface chemistry offer
increased effectiveness in target specific drug supply while decreasing nonspecific
side effects. Fullerenes (parent and derivatives of C
, etc.,) have been investigated in biomedical fields. In delivery of drug fullerenes
C
84
show huge potential as nano-vehicles due to diverse exterior chemical characteristics
(covalent and non-covalent), endohedral atoms/ions encapsulation within the closed
carbon cages and lower nanoscale dimensions, along with the reproducible chemistry
of molecules. In the present chapter the possibilities, challenges and limitations of
fullerene derived materials for delivery of nucleic acid and peptide delivery, as well
as topical drug, infectious diseases drug, anticancer drug, lung-specific drug, brain
drug and ocular drug are discussed.
, higher C70,C74,C76,C78,
60
·
Keywords Fullerene
delivery
Surface functionalization·Nucleic acid·Peptide·Drug
1 Introduction
Fullerene, originally discovered in laser desorption of graphite in gas phase, was
created for the first time by resistive heating of graphite on a preparative scale in
1990 [1, 2]. Molecule composed entirely of carbon atoms in different forms, such
as a hollow sphere, tube, or ellipsoid, is called a fullerene and has interconnected
carbon atoms in pentagonal and hexagonal rings. In 1985 the British scientist Harry
Kroto discovered carbon allotropes of nanodimension, the spherical fullerenes [3],
the buckyballs or Buckminster fullerenes, Richard Buckminster Fuller, an American
architect, coined the named from the atoms arrangement in buckyballs, shaped like
M. Sarkar (B) · D. Santra
Department of Chemistry, University of Kalyani, Kalyani, West Bengal 7410235, India
e-mail: msarkar@klyuniv.ac.in
323
324 M. Sarkar and D. Santra
a geodesic dome. In 1996, Harold W. Kroto, Richard E. Smalley and Robert F. Carl,
awarded the Chemistry Nobel Prize [ 4] for the laboratory synthesis of buckyballs.
There are five types of fullerenes such as buckyball clusters, nanotubes,
megatubes, polymers, and nano-onions (Fig. 11.1). Buckyball clusters are very
common C
member with hollow structure and other atoms can easily be trapped
60
inside it. Mega tubes, in contrast to nanotubes, have larger diameter. Polymers
have different structures like 1-dimensional chain, 2-dimensional and 3-dimensional
shapes. Nano-onions, which are spherical in shape, consist of multiple carbon layered
structure with a buckyballcore between the layers. Fullerenes (C
2
different sized symmetrical cage and sp
carbons show unique properties, (physical
60,C76
, etc.), having
and chemical) [5, 6]. The most abundant synthesized composition of 60 carbon
atoms fullerene C
[7] is comprised of 12 pentagons, 60 single bonds (C5–C5) and
60
20 hexagons, 0 double bonds (C5 = C6). Fullerene contains ‘n’ hexagons and have
2n + 20 carbon atoms. However, fullerene molecules of different sizes are evolved
from different number of hexagons. All the double bonds are conjugated in the
fused rings. The most symmetric C
molecule possesses 120 symmetry operations
60
(rotations around an axis and reflections in a plane) [8, 9].
Fullerenes have several characteristic properties as described below:
Fig. 11.1 Types of fullerenes